The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwMPN 2025 | Understanding drug-drug interactions in patients receiving both cardiac and oncology treatments
Alexander Lyon, MA, BM, BCh, PhD, FRCP, FHFA, Royal Brompton Hospital, London, UK, emphasizes the importance of drug-drug interactions in cardio-oncology, highlighting the need for careful consideration of these interactions in patients receiving both cardiac and oncology treatments. He recommends consulting local pharmacists to understand potential interactions and suggests using rosuvastatin in patients taking tyrosine kinase inhibitors. This interview took place at the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So drug-drug interactions are really important. I chaired the 2022 ESC guidelines on cardio-oncology, which was produced in partnership with the European Hematology Association and other oncology associations. And in the data supplement, we have a table with all the common cardiac drugs, such as statins, antiplatelets, DOACs and so forth and their drug-drug interactions with commonly prescribed hematology drugs and oncology drugs...
So drug-drug interactions are really important. I chaired the 2022 ESC guidelines on cardio-oncology, which was produced in partnership with the European Hematology Association and other oncology associations. And in the data supplement, we have a table with all the common cardiac drugs, such as statins, antiplatelets, DOACs and so forth and their drug-drug interactions with commonly prescribed hematology drugs and oncology drugs. So that’s one reference to look at. I would encourage everybody to also speak to their local pharmacist in their hospital to understand potential interactions. For tyrosine kinase inhibitors such as ruxolitinib, they can have quite a lot of interactions with common statins such as simvastatin and atorvastatin, whereas they have less interactions with rosuvastatin. So as a general principle, I recommend the use of rosuvastatin in patients on a tyrosine kinase inhibitor. But we’ve got these very detailed references in the data supplement of the guideline, and it’s available open access at the European Heart Journal website.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
